SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 190,579.34 |
| Enterprise Value ($M) | 209,318.34 |
| Book Value ($M) | 59,423.00 |
| Book Value / Share | 26.09 |
| Price / Book | 3.21 |
| NCAV ($M) | -21,120.00 |
| NCAV / Share | -9.27 |
| Price / NCAV | -9.02 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.08 |
| Return on Assets (ROA) | 0.05 |
| Return on Equity (ROE) | 0.10 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.04 |
| Current Ratio | 1.29 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 36,910.00 |
| Assets | 117,453.00 |
| Liabilities | 58,030.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 51,828.00 |
| Operating Income | 12,859.00 |
| Net Income | 6,955.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 14,236.00 |
| Cash from Investing | 1,468.00 |
| Cash from Financing | -20,562.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock Inc. | 5.40 | -5.12 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 160,991 | 1,755,634 | 9.17 | |
| 245,660 | 2,546,169 | 9.65 | |
| 224,525 | 2,248,614 | 9.99 | |
| 181,136 | 2,119,525 | 8.55 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| MYOV – Myovant Sciences Ltd. | NUVB – Nuvation Bio Inc |
| NVO – Novo-Nordisk A/S | OGN – Organon & Co. |
| PBH – Prestige Brands Holdings, Inc. |
Financial data and stock pages provided by
Fintel.io